Thr278
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr278  -  VASP (human)

Site Information
LARRRKAtQVGEktP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448381
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 24 ) , electrophoretic mobility shift ( 23 ) , immunoprecipitation ( 2 , 16 ) , mass spectrometry ( 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ) , mass spectrometry (in vitro) ( 2 ) , mutation of modification site ( 3 , 16 , 22 , 23 ) , peptide sequencing ( 24 ) , phospho-antibody ( 1 , 2 , 4 , 22 , 23 ) , phosphoamino acid analysis ( 24 ) , phosphopeptide mapping ( 24 ) , western blotting ( 1 , 2 , 4 , 16 , 23 )
Disease tissue studied:
brain cancer ( 23 ) , glioma ( 23 ) , gastric cancer ( 5 , 16 , 18 ) , gastric carcinoma ( 5 , 16 , 18 ) , liver cancer ( 3 ) , squamous cell carcinoma of the liver ( 3 ) , lung cancer ( 2 , 19 ) , non-small cell lung cancer ( 19 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
PTEN (human) ( 1 )
Putative in vivo kinases:
p90RSK (human) ( 2 ) , PKG1 (human) ( 16 )
Kinases, in vitro:
AMPKA1 (human) ( 22 ) , p90RSK (human) ( 2 ) , PKACA (human) ( 24 ) , PKG1 (human) ( 24 )
Treatments:
acadesine ( 22 ) , bacterial infection ( 16 ) , cGMP_analog ( 22 ) , colforsin ( 22 ) , compound_C ( 22 ) , indirubin ( 22 ) , KT5823 ( 16 ) , metformin ( 22 ) , phenformin ( 22 ) , rottlerin ( 16 ) , serum ( 2 ) , siRNA ( 2 )

Downstream Regulation
Effects of modification on biological processes:
carcinogenesis, altered ( 2 ) , cell motility, altered ( 2 ) , cytoskeletal reorganization ( 2 , 16 , 22 ) , transcription, inhibited ( 23 )

References 

1

Zhang Q, et al. (2021) PTENĪµ suppresses tumor metastasis through regulation of filopodia formation. EMBO J, e105806
33755220   Curated Info

2

Lara R, et al. (2011) An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis. Oncogene 30, 3513-21
21423205   Curated Info

3

Routray C, et al. (2011) Protein kinase G signaling disrupts Rac1-dependent focal adhesion assembly in liver specific pericytes. Am J Physiol Cell Physiol 301, C66-74
21451103   Curated Info

4

Jaeger V, et al. (2010) Herpes simplex virus type 1 entry into epithelial MDCKII cells: role of VASP activities. J Gen Virol 91, 2152-7
20463151   Curated Info

5

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

6

Possemato A (2009) CST Curation Set: 8599; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

7

Possemato A (2009) CST Curation Set: 8363; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

8

Possemato A (2009) CST Curation Set: 8048; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

9

Possemato A (2009) CST Curation Set: 8049; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

10

Possemato A (2009) CST Curation Set: 8050; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

11

Moritz A (2009) CST Curation Set: 7937; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Moritz A (2009) CST Curation Set: 7939; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

13

Moritz A (2009) CST Curation Set: 7298; Year: 2009; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

14

Moritz A (2009) CST Curation Set: 7296; Year: 2009; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

15

Moritz A (2009) CST Curation Set: 7297; Year: 2009; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

16

Knauer O, et al. (2008) Differential phosphoproteome profiling reveals a functional role for VASP in Helicobacter pylori-induced cytoskeleton turnover in gastric epithelial cells. Cell Microbiol 10, 2285-96
18637808   Curated Info

17

Moritz A (2007) CST Curation Set: 3003; Year: 2007; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

18

Moritz A (2007) CST Curation Set: 2964; Year: 2007; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

19

Moritz A (2007) CST Curation Set: 2741; Year: 2007; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

20

Guo A (2007) CST Curation Set: 2748; Year: 2007; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

21

Guo A (2007) CST Curation Set: 2749; Year: 2007; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

22

Blume C, et al. (2007) AMP-activated protein kinase impairs endothelial actin cytoskeleton assembly by phosphorylating vasodilator-stimulated phosphoprotein. J Biol Chem 282, 4601-12
17082196   Curated Info

23

Zhuang S, et al. (2004) Vasodilator-stimulated phosphoprotein activation of serum-response element-dependent transcription occurs downstream of RhoA and is inhibited by cGMP-dependent protein kinase phosphorylation. J Biol Chem 279, 10397-407
14679200   Curated Info

24

Butt E, et al. (1994) cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem 269, 14509-17
8182057   Curated Info